The effect of epidermal growth factor on the submandibular salivary glands of albino rats receiving doxorubicin /
تأثير عامل نمو البشرة على الغدد اللعابية تحت الفكية فى الفئران البيضاء المزودة بعقار الدوكسوروبيسين
Mohamed Hamdy Sayed Mansy ; Supervied Malak Mohamed Soliman , Rabab Tawfeek Mubarak
- Cairo : Mohamed Hamdy Sayed Mansy , 2020
- 213 P. : charts , facsimiles ; 25cm
Thesis (Ph.D.) - Cairo University - Faculty of Oral and Dental Medicine - Department of Oral Biology
Epidermal growth factor (EGF) is a potent stimulant of proliferation and healing of the gastrointestinal tract. It is also acting as a cytoprotective agent that could stabilize cells against noxious agents. Doxorubicin (DXR) is widely used to treat different types of human neoplastic disease .Despite its high efficacy, the clinical application of doxorubicin was greatly restricted due to its multiple side effects. Since EGF exerts a potent growth and healing effect, it is supposed to play a role in the development and regeneration of salivary glands as well as oral mucosa. The present study was designed to investigate the effect of EGF injection on the cytotoxic effect of DXR induced in submandibular salivary gland of rats regarding the structure, ultrastructure, and immunohistochemical expression of VEGF and Ki-67. Sixty healthy adult male Albino rats, three months old and 200gm body weight were used in this study and were divided into three equal groups. Group I served as control group and the rats were received a single intraperitoneal injection of natural saline. In group II (DXR group), the rats received 20 mg/kg body weight DXR as a single intra peritoneal injection. Whereas , group III (DXR + EGF) was divided into two subgroups (A and B) .In group IIIA ,the rats received a single dose of DXR intraperitoneally (20 mg/kg body weight) and on the next day they were injected intraperitoneally with EGF in a daily dose of 10ug/kg body weight for 7 consecutive days. However, in group IIIB, the rats received the same intraperitoneal dose of DXR (20 mg/kg body weight) and 5 days later, they were injected with the same intraperitoneal dose of EGF (10ug/kg body weight) and for the same duration (7 consecutive days)